Rentschler Biopharma SE

Optimal time-to-market for life-saving biopharmaceuticals

As a leading global CDMO for biopharmaceuticals, Rentschler Biopharma ensures optimal time to proof-of-concept for products in clinical phases I and II, as well as time to market for clinical phase III. Our strength lies in the exceptional track record of over 100 different therapeutic protein formats. In addition to our proven scientific and technological expertise, we are known for our world-class project management, consulting and regulatory support solutions. At Rentschler Biopharma, we combine these strengths to ensure high-quality solutions to the most complex challenges and accelerate standard approaches.

For more information on our accelerated timelines, taking into account economically attractive process options, please visit our website.

News from this company

News

Rentschler in Collaboration to Improve AAV-Manufacturing for Gene Therapies

25.08.2023 -

German CDMO Rentschler Biopharma is collaborating with the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organization...

News

Rentschler Invests in UK Cell and Gene Therapy Site

16.02.2021 -

German CDMO Rentschler Biopharma is to establish manufacturing capacity for advanced therapy medicinal products (ATMPs), including Adeno-associated virus (AAV) vectors...

News

Rentschler to Support BioNTech-Pfizer Vaccine

09.10.2020 -

German CDMO Rentschler Biopharma has reached agreement with Pfizer and BioNTech to handle the downstream purification process for the partnership’s mRNA-based COVID-19...

Strategy & Management

Outsourcing Services: from Gene to Patient

19.02.2020 -

Rentschler Biopharma SE, headquartered in Laupheim, Germany, is a leading, family-owned, full-service biopharma CDMO. Owing to agile decision making and efficient...

News

Rentschler Kicks off Expansion at US Facility

29.11.2019 -

Laupheim, Germany-based contract development and manufacturing organization (CDMO) for biopharmaceuticals, Rentschler Biopharma, is taking the first step in the expansion...

News

Nikolaus F. Rentschler and Frank Mathias Awarded as "EY Entrepreneur of the Year"

29.10.2019 - Rentschler Biopharma’s chairman of the board, Nikolaus F. Rentschler, together with CEO Frank Mathias have received the "EY Entrepreneur of the Year" award 2019 in the category...

Markets & Companies

Driving Innovation and Extending Its Global Reach

28.10.2019 -

Last year, Rentschler Biopharma, a German contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced its "Strategy 2025."

News

Rentschler Biopharma Extends Japanese Pact

09.10.2019 -

German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with...

Plant Construction & Process Technology

Rentschler Facility Wins ‘Facility of the Year Award’ 2012 in Equipment Innovation

14.05.2012 -

Pharmaceutical Technology - The new manufacturing facility of German biotech company Rentschler has won the 2012 Facility of the Year Award (FOYA) in the category...

Products from this company

Services

Optimal Time-to-Market for Life-Saving Biopharmaceuticals

Rentschler Biopharma SE -

Rentschler Biopharma offers bioprocess development and cGMP manufacturing for high-quality biopharmaceuticals. The company’s strength lies in its extensive experience...

Contact